470 related articles for article (PubMed ID: 9356012)
21. Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
Yagi N; Takasu N; Higa S; Ishikawa K; Murakami K; Mimura G
Horm Metab Res; 1995 Oct; 27(10):439-41. PubMed ID: 8575720
[TBL] [Abstract][Full Text] [Related]
22. Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro.
Fürnsinn C; Neschen S; Noe C; Bisschop M; Roden M; Vogl C; Schneider B; Waldhäusl W
Br J Pharmacol; 1997 Dec; 122(7):1367-74. PubMed ID: 9421284
[TBL] [Abstract][Full Text] [Related]
23. Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats.
Santuré M; Pitre M; Nadeau A; Bachelard H
Metabolism; 2003 Aug; 52(8):978-86. PubMed ID: 12898461
[TBL] [Abstract][Full Text] [Related]
24. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
25. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Ye JM; Frangioudakis G; Iglesias MA; Furler SM; Ellis B; Dzamko N; Cooney GJ; Kraegen EW
Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
[TBL] [Abstract][Full Text] [Related]
26. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.
O'Rourke CM; Davis JA; Saltiel AR; Cornicelli JA
Metabolism; 1997 Feb; 46(2):192-8. PubMed ID: 9030828
[TBL] [Abstract][Full Text] [Related]
27. Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.
Levin K; Hother-Nielsen O; Henriksen JE; Beck-Nielsen H
Diabetes Care; 2004 Jan; 27(1):148-54. PubMed ID: 14693981
[TBL] [Abstract][Full Text] [Related]
28. Effect of troglitazone on leptin production. Studies in vitro and in human subjects.
Nolan JJ; Olefsky JM; Nyce MR; Considine RV; Caro JF
Diabetes; 1996 Sep; 45(9):1276-8. PubMed ID: 8772734
[TBL] [Abstract][Full Text] [Related]
29. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes.
Meyer MM; Levin K; Grimmsmann T; Perwitz N; Eirich A; Beck-Nielsen H; Klein HH
Diabetes; 2002 Sep; 51(9):2691-7. PubMed ID: 12196460
[TBL] [Abstract][Full Text] [Related]
30. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
31. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.
Koopmans SJ; Kushwaha RS; DeFronzo RA
Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109
[TBL] [Abstract][Full Text] [Related]
32. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
[TBL] [Abstract][Full Text] [Related]
33. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.
Tack CJ; Ong MK; Lutterman JA; Smits P
Diabetologia; 1998 May; 41(5):569-76. PubMed ID: 9628275
[TBL] [Abstract][Full Text] [Related]
34. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
Park KS; Ciaraldi TP; Abrams-Carter L; Mudaliar S; Nikoulina SE; Henry RR
J Clin Endocrinol Metab; 1998 May; 83(5):1636-43. PubMed ID: 9589670
[TBL] [Abstract][Full Text] [Related]
35. Effects of fructose and troglitazone on phospholipid fatty acid composition in rat skeletal muscle.
Clore JN; Li L; Rizzo WB
Lipids; 2000 Nov; 35(11):1281-7. PubMed ID: 11132187
[TBL] [Abstract][Full Text] [Related]
36. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H
Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
[TBL] [Abstract][Full Text] [Related]
37. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
39. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM.
Bonadonna RC; Del Prato S; Bonora E; Saccomani MP; Gulli G; Natali A; Frascerra S; Pecori N; Ferrannini E; Bier D; Cobelli C; DeFronzo RA
Diabetes; 1996 Jul; 45(7):915-25. PubMed ID: 8666143
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of troglitazone action in type 2 diabetes.
Petersen KF; Krssak M; Inzucchi S; Cline GW; Dufour S; Shulman GI
Diabetes; 2000 May; 49(5):827-31. PubMed ID: 10905493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
